Navigation Links
Cempra Pharmaceuticals Profiles the Broad Spectrum and Potent Activity Profile of Solithromycin (CEM-101) at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day
Date:1/12/2011

iprofloxacin against B. anthracis, despite a less than optimal dose.  Solithromycin also delayed mortality in mice for days after dosing against F. tularensis.  Future studies will evaluate optimal doses of solithromycin based on PK/PD modeling and the current therapeutic regimen being tested in Phase 2.  

"Solithromycin is emerging as a very promising broad spectrum, well-tolerated antibiotic," said Prabhavathi Fernandes, Ph.D., Chief Executive Officer of Cempra Pharmaceuticals.  "Pre-clinical and clinical data collected to date show it to have a broad activity spectrum and to be well tolerated in healthy volunteers.  Its flexibility of administration including once-daily oral, oral suspension and intravenous, its high tissue penetration, especially in blood and lung including lung macrophages, and its ability to target intracellular pathogens, demonstrate its significant potential for both civilian and bio-defense applications.  Building a safety and efficacy database for civilian bacterial pneumonia coupled with meeting the animal rule, which is a unique regulatory mechanism to gain FDA approval based on animal data when well-controlled efficacy studies in humans is not ethical or feasible, could be a path forward for approval for bio-defense indications."

About solithromycin (CEM-101)Solithromycin is the first fluoroketolide with a number of attributes that may provide clinically important advantages over several comparator products:

  • 8 to 16 times more potent than azithromycin and is active against organisms that have become resistant to azithromycin
  • Potent in vitro activity against all important respiratory pathogens, including pneumococci, beta-hemolytic streptococci, staphylococci, Hemophilus, Legionella, Mycoplasma, Moraxella and Chlamydophila
  • Potent in vitro activity against other medically significant pathogens including CA-MRSA, M. avium, malaria, enteroc
    '/>"/>

  • SOURCE Cempra Pharmaceuticals
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related biology technology :

    1. Cempra Pharmaceuticals Announces Appointment of John H. Johnson to Board of Directors
    2. Takeda and Zinfandel Pharmaceuticals Sign Licensing Agreement for Alzheimers Disease Biomarker in Combination with Pioglitazone
    3. Savient Pharmaceuticals Provides Business Update
    4. Anthera Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
    5. Anadys Pharmaceuticals Augments Management Team and Board of Directors
    6. Isis Pharmaceuticals Adds Two New Drugs to Development Pipeline
    7. Onyx Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
    8. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
    9. Pier Pharmaceuticals Names Peter Letendre as Chief Executive Officer, President and Director
    10. Optimer Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
    11. Pittsburgh-based BIOSAFE Receives EPA Registration and Enters Into Commercialization Agreement with Union Springs Pharmaceuticals
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... Research ( http://www.bccresearch.com ) reveals in its new report, ... MARKETS , the global market for digital polymerase chain ... This is estimated to grow to $490 billion in ... of 28.6%. , New digital PCR technology has created ... broader PCR field. The opportunities presented by this technology ...
    (Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
    (Date:7/11/2014)... 2014 Cayenne Medical, Inc., a ... the soft tissue reconstruction segment, announced the worldwide ... surgeries involving the shoulder and extremities. The SureLock ... inserter-controlled deployment method. The unique delivery eliminates manual ... pull-out, or anchor displacement (also commonly know as ...
    (Date:7/10/2014)... Canada (PRWEB) July 10, 2014 ... present in very low abundance and are often ... challenging and time-consuming. , Join presenters Dr. Rowel ... and Dr. John Anders, Head of Quality at ... spectrometer-based approach that can speed detection and quantitation ...
    Breaking Biology Technology:Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2
    ... , , , NEW ... of lipid, glucose and overall energy metabolism. Bile acid activation of the ... muscle and brown fat, thereby conferring resistance to weight gain. Now, a ... 10, Issue 3, Sept. 2, 2009) elaborates on a separate TGR5-regulated mechanism ...
    ... WOODLANDS, Texas, September 1 Berlin Heart Inc.,reported today that ... EXCOR(R) Pediatric IDE Study after having received unconditional,approval of the ... The Principal Investigator, Dr. Charles Fraser, Chief of ... and Pediatrics,at Baylor College of Medicine said, "We ...
    ... ST. LOUIS and ROMAINVILLE, France, Sept. 1, 2009 Monsanto Company ... commercial license agreement with France-based Cellectis S.A. (Alternext: ALCLS), a biotechnology ... technology in plants. , , Meganucleases are molecular ... genome of a plant cell, thereby allowing a wide range of ...
    Cached Biology Technology:Cell Metabolism Publishes Novel TGR5-Mediated Mechanism for the Treatment of Diabetes and Obesity 2Cell Metabolism Publishes Novel TGR5-Mediated Mechanism for the Treatment of Diabetes and Obesity 3Major Milestone Achieved - Berlin Heart EXCOR Pediatric IDE Study 2Monsanto Licenses Use of Cellectis' Innovative Genome Modification Technology 2Monsanto Licenses Use of Cellectis' Innovative Genome Modification Technology 3
    (Date:7/10/2014)... other major cities in New Mexico, nearly every public ... rather than precious potable water supplies. Across the U.S. ... golf courses receive treated effluent. Reusing the effluent increases ... courses and homeowners alike fertilize their lawns during the ... A New Mexico State University turfgrass expert has a ...
    (Date:7/10/2014)... 30, 2014  Aware, Inc. (NASDAQ: AWRE ... previously announced on June 26, 2014 that its Board ... $1.75 per share, or approximately $40 million in total.  ... 2014 and a payment date of July 24, 2014.  ... had set an ex-dividend date for this special cash ...
    (Date:7/10/2014)... 2, 2014 It is a great honor ... appointment of the world-renowned Thoracic and Cardiovascular surgeon, Mark ... Dr. Ginsburg, with over 34 years of experience, ... and Good Samaritan Regional Medical Center. Dr. Ginsburg has ... 1980,s and is considered an expert in the implantation ...
    Breaking Biology News(10 mins):'Tailored' water -- the latest in lawn care 2NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2
    ... new study finds that propofol, a well-known anesthesia medication, has ... imaging studies. The study, led by a pediatric anesthesiologist now ... incidence of adverse events and no long term complications when ... require them to be still for long periods of time. ...
    ... life, and occurs naturally in soil and ground water in ... been linked to lung, bladder and kidney cancer, and thus ... drinking water. Chemically similar to phosphorus, arsenic forms arsenate (AsO ... 3- ). Arsenate interferes with many phosphate-requiring metabolic reactions, ...
    ... June 8, 2010 From April 8 to 10, ... Texas, to focus on advancing new tools to humanely ... and dogs. Experts in reproductive biology and other related ... with industry experts in animal health drug development. Veterinary ...
    Cached Biology News:Propofol poses low risk in pediatric imaging studies, but risk increases with anesthesia duration 2Arsenic hyperaccumulating ferns: How do they survive? 2Arsenic hyperaccumulating ferns: How do they survive? 3Momentum builds after 4th International Symposium on Pet Contraception 2Momentum builds after 4th International Symposium on Pet Contraception 3
    ... The Dyad Disciple thermal cycler is ... It may also be operated independently, using ... variety of interchangeable Alpha units (sample-holder, heat-pump ... well as the Chromo4 real-time detector. Peltier ...
    Mouse monoclonal [IA-C6] to MHC Class II I Ab + Ad (FITC) ( Abpromise for all tested applications). Antigen: Tissue / cell preparation of Purified Mouse lymph node B cells...
    BD BioCoat Vented Caps for 175 cm2 Flasks...
    BD BioCoat Poly-D-Lysine 60 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of poly-D-lysine....
    Biology Products: